Restless legs syndrome can turn the quietest part of the day into the most uncomfortable. People with the condition may feel an overwhelming urge to move their legs just as they are trying to relax or fall asleep, often accompanied by crawling, pulling, aching, tingling, burning, or other difficult-to-describe sensations. Walking or moving the legs can temporarily make the sensations disappear, but they often return as soon as the person becomes still again. For people with moderate or severe restless legs syndrome, the resulting sleep disruption can become as troublesome as the leg sensations themselves.
Interest in medical marijuana for restless legs syndrome, or RLS, has grown largely because some patients with difficult-to-treat disease have reported substantial nighttime relief after using cannabis. Until recently, however, almost all of the evidence consisted of case reports and patient surveys. That picture began to change in 2026 when researchers published a prospective clinical trial involving a standardized THC/CBD preparation. The results were encouraging, but cannabis remains an investigational rather than guideline-recommended treatment for RLS. Understanding where the evidence stands requires separating promising early findings from what has actually been established through controlled clinical research.
What Is Restless Legs Syndrome?
Restless legs syndrome is a neurological sensorimotor disorder characterized by an urge to move the legs that usually develops or becomes worse during rest, improves temporarily with movement, and occurs predominantly during the evening or at night. The National Institute of Neurological Disorders and Stroke describes RLS as a disorder that can substantially disrupt sleep and daily functioning. There is no single blood test, scan, or sleep study that confirms the diagnosis. Instead, clinicians evaluate the pattern of symptoms while considering conditions that can mimic or worsen RLS, including neuropathy, kidney disease, pregnancy, iron deficiency, and sleep disorders such as obstructive sleep apnea.
RLS biology is more complicated than simply having overactive leg muscles. Research has repeatedly implicated brain iron regulation and dopamine signaling. Work involving Johns Hopkins, Yale, Case Western Reserve University, and other institutions has found evidence of reduced iron concentrations in several brain regions in people with RLS. Research at Johns Hopkins has also identified another important component: glutamate. In one magnetic resonance spectroscopy study involving 28 people with RLS and 20 controls, researchers found higher thalamic glutamate/glutamine levels in the RLS group. Those levels were strongly associated with time spent awake during the normal sleep period, suggesting that excessive neurological arousal may help explain why people with RLS can remain awake even when physically exhausted.
Why Researchers Are Studying Cannabis for RLS
The endocannabinoid system influences pain perception, movement, sleep, arousal, and neurotransmitter release throughout the central nervous system. THC primarily produces its effects through cannabinoid CB1 receptors in the brain, while CBD has a much more complicated pharmacological profile involving numerous signaling systems. Researchers have proposed several possible reasons cannabinoids might influence RLS, including changes in pain processing, muscle sensations, sleep, anxiety, dopamine-related circuits, and glutamatergic signaling. These mechanisms are plausible, but a plausible mechanism is not the same as a proven treatment.
Glutamate is particularly interesting because cannabinoid receptor activation can suppress the release of certain neurotransmitters, including glutamate. The researchers behind the 2026 RLS cannabinoid trial specifically identified the ability of cannabinoids to inhibit striatal glutamate release as one reason for investigating THC and CBD in the disorder. This hypothesis fits with the Johns Hopkins evidence linking excessive glutamatergic activity with nighttime arousal in RLS, although it has not been proven that cannabis improves RLS specifically by correcting that abnormality.
Cannabis might also help certain patients indirectly. Some people describe RLS sensations as painful, while others primarily struggle with the inability to relax or sleep. Cannabinoids can affect pain and sleep in some medical populations. The National Center for Complementary and Integrative Health notes that studies involving people with chronic pain, multiple sclerosis, PTSD, and other conditions have sometimes found improvements in sleep quality or sleep disturbance. However, researchers cannot always determine whether cannabis directly improves sleep or whether patients simply sleep better because another symptom, such as pain, improves.
What Studies Say About Marijuana and Restless Legs Syndrome
Some of the earliest evidence came from the University of Bordeaux and Bordeaux University Hospital. In 2017, neurologists Thomas Megelin and Imad Ghorayeb published a report describing six patients with severe or treatment-resistant RLS who experienced striking improvement after cannabis use. A later report expanded those observations to additional patients. A review of the cases reported that many experienced major or complete relief, including patients who had failed conventional treatments. The findings generated significant interest because refractory RLS can be extremely difficult to manage, but these reports had major limitations: they involved very small groups, relied largely on subjective patient descriptions, did not include placebo controls, and frequently involved smoked cannabis.
Cannabis has also been examined in people with kidney disease, a population in which RLS is particularly common. University of Ottawa and Ottawa Hospital researchers surveyed 192 patients receiving maintenance dialysis. Eighty-six reported current or previous RLS symptoms, and 14 had tried cannabis specifically for their RLS. Seven reported improvement, while three reported no benefit and four did not state an outcome. The study again suggested that some patients perceive meaningful relief, but it could not establish cause and effect because cannabis treatment was not randomized, standardized, or compared with placebo.
A 2026 scoping review searched thousands of publications and ultimately found only seven studies suitable for evaluating cannabis or cannabinoids in RLS. The authors concluded that the available literature suggested possible symptom improvement but consisted largely of case reports, surveys, and post hoc analyses rather than rigorous randomized trials. Their conclusion was that the evidence remained insufficient to support clinical recommendations. Importantly, the review’s literature search ended in April 2025, before one of the most significant RLS cannabinoid studies to date was published.
The 2026 THC/CBD Restless Legs Syndrome Trial
In July 2026, researchers from Hospital Universitario de Getafe and Universidad Europea de Madrid published an exploratory clinical trial in the Journal of Neurology evaluating a standardized preparation containing 2.7 mg THC and 2.5 mg CBD per administered unit. Eighteen people with RLS participated, 16 of whom also had multiple sclerosis. Their average baseline International Restless Legs Syndrome Rating Scale score was approximately 22, placing the group in the severe range. Researchers evaluated symptoms after one and three months and used actigraphy to objectively examine several sleep measurements.
RLS severity improved significantly after both one month and three months of cannabinoid treatment. Wake after sleep onset—the amount of time participants remained awake after initially falling asleep—also declined significantly. Sleep latency and overall sleep efficiency, however, did not show significant improvement. At one year, roughly two-thirds of the original participants were still using the treatment, and those who remained on therapy continued to demonstrate improved RLS scores. These results represent stronger evidence than the earlier anecdotal reports because patients were followed prospectively and standardized clinical scales were used.
The study nevertheless has substantial limitations. Only 18 patients participated, most had multiple sclerosis, and there was no placebo group or blinding. RLS can produce meaningful placebo responses, making controlled trials particularly important when evaluating a new therapy. The study therefore provides a promising signal rather than definitive proof. Larger randomized, double-blind trials will be necessary to determine how much of the improvement resulted from cannabinoids themselves, which patients are most likely to respond, what cannabinoid ratio is most appropriate, and whether benefits remain durable over years of treatment.
THC vs CBD for Restless Legs
The limited evidence available so far does not indicate that CBD alone works reliably for RLS. Researchers at the University of São Paulo performed a post hoc analysis of a randomized, double-blind, placebo-controlled trial involving people who had Parkinson’s disease, REM sleep behavior disorder, and RLS. Six participants received CBD at doses ranging from 75 to 300 mg while 12 received placebo. After 14 weeks, CBD did not significantly reduce RLS severity compared with placebo.
That result contrasts with the 2026 study using THC and CBD together and with the earlier reports involving cannabis containing THC. It is far too early to conclude that THC is the active ingredient responsible for RLS improvement, but the difference raises an important research question. THC and CBD act differently in the nervous system, and a balanced combination may produce neurological effects that isolated CBD does not. The findings also mean consumers should not assume that commercially available CBD oil is an evidence-based treatment for restless legs simply because cannabis has shown promise in some RLS studies.
Research is actively trying to answer this question. In July 2026, the University of Colorado Anschutz announced enrollment for a Phase 2 trial specifically evaluating an investigational CBD formulation for idiopathic RLS. Meanwhile, a separate randomized placebo-controlled pilot trial using a CBD/THC cannabis preparation is recruiting through Sunnybrook Research Institute and University Health Network in Canada. These controlled studies should provide considerably stronger evidence than patient surveys and open-label experiments.
How Medical Marijuana Compares With Standard RLS Treatments
Cannabis currently sits outside mainstream RLS treatment guidelines. The American Academy of Sleep Medicine’s updated clinical practice guideline emphasizes evaluating iron status in everyone with clinically significant RLS. The guideline recommends checking ferritin and transferrin saturation and addressing iron deficiency when appropriate. IV ferric carboxymaltose received a strong recommendation for suitable adults, while oral ferrous sulfate and several other forms of IV iron received conditional recommendations. The guideline also identifies alcohol, caffeine, antihistaminergic drugs, serotonergic medications, antidopaminergic medications, and untreated obstructive sleep apnea as potentially aggravating factors that should be addressed.
Another major change in RLS treatment has involved dopamine agonists. Drugs such as pramipexole and ropinirole were once among the most widely recommended medications for the condition. The AASM now conditionally recommends against their standard long-term use because of augmentation, a phenomenon in which treatment eventually makes RLS appear earlier in the day, become more severe, or spread to other areas of the body. Instead, gabapentin, gabapentin enacarbil, and pregabalin now carry strong recommendations for adults with RLS. Certain opioids remain conditional options for refractory disease.
Cannabis has not yet reached that level of evidence. German neurological and sleep medicine guidelines published before the new 2026 trial specifically concluded that cannabinoid evidence was insufficient to recommend RLS treatment. Even with the encouraging 2026 findings, there is still no completed large randomized placebo-controlled trial demonstrating effectiveness. Medical marijuana therefore makes the most scientific sense at present as a treatment under investigation, particularly for difficult cases, rather than as a replacement for checking iron status or using therapies supported by established RLS guidelines.
Risks, Side Effects and Medication Interactions
The fact that RLS occurs primarily at night may make the sedating properties of cannabis seem beneficial, but sedation is not automatically equivalent to healthy sleep. THC can impair coordination, reaction time, memory, and judgment, while some patients experience anxiety, dizziness, increased heart rate, or uncomfortable intoxication. Regular cannabis use can also lead to tolerance, dependence, and cannabis use disorder. NCCIH notes that cannabis can produce orthostatic hypotension, which may increase the risk of dizziness and falls—an especially important consideration for older adults getting out of bed during the night.
Medication interactions deserve particular attention because several established RLS drugs also affect the central nervous system. Gabapentin, pregabalin, opioids, benzodiazepines, sleep medications, and cannabis can all contribute to sleepiness or impairment. Combining sedating substances may intensify those effects. CBD is not pharmacologically inactive simply because it does not produce the typical THC high; the FDA warns that CBD can alter the way other medications work and has been associated with liver injury and excessive sleepiness. Commercial CBD and cannabis products may also contain cannabinoid concentrations that differ from their labels.
The FDA has not approved cannabis or CBD for restless legs syndrome. In fact, the cannabis plant has not received FDA approval for treating any disease. The agency has approved specific cannabinoid-based prescription drugs for other conditions, including purified CBD for certain seizure disorders and synthetic cannabinoid medicines for chemotherapy-related nausea or HIV-associated appetite loss, but those approvals should not be interpreted as evidence that dispensary marijuana or CBD products have been proven effective for RLS.
Could Medical Marijuana Eventually Become an RLS Treatment?
The scientific case for investigating cannabinoids in RLS is considerably stronger today than it was several years ago. Early case reports produced unusually dramatic patient responses, dialysis surveys identified additional people reporting benefit, neurological research provides plausible cannabinoid targets, and the 2026 prospective THC/CBD study demonstrated measurable reductions in RLS severity and nighttime wakefulness. At the same time, CBD alone failed to outperform placebo in one small Parkinson’s-related RLS analysis. Taken together, these findings suggest that the cannabinoid question cannot be dismissed—but neither can cannabis yet be considered proven therapy.
The next step is controlled research. Randomized trials now underway in North America may help determine whether benefits persist when cannabinoids are compared directly with placebo and whether THC, CBD, or particular combinations produce different outcomes. Researchers also need to examine long-term tolerance, withdrawal, sleep architecture, cognition, fall risk, medication interactions, and whether cannabis could itself develop a phenomenon resembling loss of effectiveness after prolonged use.
Final Thoughts on Medical Marijuana for Restless Legs Syndrome
Medical marijuana is one of the more intriguing experimental treatments being investigated for restless legs syndrome. The evidence has progressed beyond isolated anecdotes: a small 2026 prospective study found significant improvement in RLS severity with a standardized THC/CBD preparation, while earlier observational reports describe substantial symptom relief in some patients with severe or treatment-resistant disease. These findings are meaningful, especially for people who have exhausted conventional options.
They are not, however, sufficient to establish marijuana as a first-line treatment. Current clinical guidelines place far stronger evidence behind identifying iron deficiency, removing aggravating factors, and using medications such as gabapentin, gabapentin enacarbil, or pregabalin when treatment is necessary. Anyone experiencing persistent restless legs should first make sure the diagnosis is correct and that treatable contributors such as low iron, kidney disease, medication effects, neuropathy, pregnancy, or sleep apnea have been considered.
For patients with severe or refractory RLS who are considering medical cannabis where legally available, the most evidence-based approach is to discuss it with a physician or sleep specialist familiar with both RLS and cannabinoid pharmacology. Product composition, THC exposure, other medications, age, fall risk, cardiovascular health, and previous responses to RLS treatment all matter. As larger controlled studies report their results, medical marijuana may eventually find a defined place in RLS treatment. For now, the evidence is best described as promising, rapidly developing, but not yet conclusive.
